<DOC>
	<DOCNO>NCT01095497</DOCNO>
	<brief_summary>The objective study : 1 . Evaluate safety tolerability CINRYZE administer subcutaneous injection subject hereditary angioedema 2 . Characterize pharmacokinetics pharmacodynamics CINRYZE administer subcutaneous injection 3 . Assess immunogenicity CINRYZE follow subcutaneous administration</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics , Pharmacodynamics Subcutaneous CINRYZE Administration</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>To eligible protocol , subject must : 1 . Have confirm diagnosis HAE . 2 . During 3 consecutive month prior screen , history le 1 HAE attack per month ( average ) treat C1INH therapy blood product , ecallantide ( Kalbitor ) , icatibant ( Firazyr ) , antifibrinolytics ( e.g. , tranexamic acid ) , IV fluid , narcotic analgesic . 3 . Agree strictly adhere protocoldefined schedule assessment procedure . To eligible protocol , subject must : 1 . Have receive C1INH therapy blood product treatment prevention HAE attack within 14 day prior first dose . 2 . Have receive ecallantide ( Kalbitor ) , icatibant ( Firazyr ) , antifibrinolytics ( e.g. , tranexamic acid ) within 14 day prior first dose . 3 . Have change ( start , stop , change dose ) androgen therapy ( e.g. , danazol , oxandrolone , stanozolol , testosterone ) within 14 day prior first dose . 4 . If female , start take change dose hormonal contraceptive regimen hormone replacement therapy ( i.e. , estrogen/progestin contain product ) within 3 month prior first dose . 5 . Have history abnormal blood clot coagulopathy . 6 . Have history allergic reaction CINRYZE blood product . 7 . Be pregnant breastfeeding . 8 . Have receive immunization within 30 day prior first dose . 9 . Have participate investigational drug study within 30 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HAE</keyword>
	<keyword>C1 inhibitor ( C1INH )</keyword>
	<keyword>Subcutaneous</keyword>
</DOC>